The researchers sought to understand the prognostic value of tau positron emission tomography for predicting cognitive decline across the clinical spectrum of Alzheimer disease.
For patients with dementia-related psychosis who have a response to pimavanserin, the risk for relapse is lower with continuation of the drug versus discontinuation
The overall global age-standardized prevalence of young-onset dementia, in which symptoms start before age 65 years, is 119.0 per 100,000 population.
Individual doctors can prescribe Aduhelm, but patients would have to go elsewhere to receive the drug via infusion
The researchers conducted a randomized, placebo-controlled, multi-arm trial of gantenerumab or solanezumab in participants with dominantly inherited Alzheimer disease across asymptomatic and symptomatic disease stages.
A longer reproductive period in women is associated with biomarkers for Alzheimer disease (AD).
The treatment, which is administered as a monthly intravenous infusion, binds to aggregated β-amyloid and promotes removal of amyloid from the brain.
Tooth loss is independently associated with a higher risk for cognitive impairment and dementia.
Determining if a patient with subtle cognitive symptoms suffers from prodromal or preclinical Alzheimer disease (AD) and whether that patient will progress to AD dementia is a challenge. However, this determination is critically important in order to ascertain a correct and early diagnosis of AD. Researchers may have found one method that can help.
The U.S. FDA’s controversial approval of a new drug for AD, along with its high price, is now being investigated by two House committees.